Cognition Therapeutics (CGTX) shares lost more than two-thirds of their value this past week after the company released results from its Phase II, 153-patient SHINE trial (COG0201; NCT03507790) that ...
Want smarter insights in your inbox? Sign up for our weekly newsletters to get only what matters to enterprise AI, data, and security leaders. Subscribe Now Enterprise AI teams face a costly dilemma: ...
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a very ...
News-Medical.Net on MSN
Hormonal imbalance and gut microbes linked to cognitive deficits in patients with PitNETs
Pituitary neuroendocrine tumors (PitNETs) are commonly associated with visual disturbances and endocrine abnormalities; however, many patients also experience cognitive deficits, particularly in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results